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Abstract
Human cytomegalovirus (HCMV) establishes lifelong infection with recurrent episodes of virus production and shedding
despite the presence of adaptive immunological memory responses including HCMV immune immunoglobulin G (IgG). Very
little is known how HCMV evades from humoral and cellular IgG-dependent immune responses, the latter being executed
by cells expressing surface receptors for the Fc domain of IgG (FccRs). Remarkably, HCMV expresses the RL11-encoded gp34
and UL119-118-encoded gp68 type I transmembrane glycoproteins which bind Fcc with nanomolar affinity. Using a newly
developed FccR activation assay, we tested if the HCMV-encoded Fcc binding proteins (HCMV FccRs) interfere with
individual host FccRs. In absence of gp34 or/and gp68, HCMV elicited a much stronger activation of FccRIIIA/CD16, FccRIIA/
CD32A and FccRI/CD64 by polyclonal HCMV-immune IgG as compared to wildtype HCMV. gp34 and gp68 co-expression
culminates in the late phase of HCMV replication coinciding with the emergence of surface HCMV antigens triggering
FccRIII/CD16 responses by polyclonal HCMV-immune IgG. The gp34- and gp68-dependent inhibition of HCMV immune IgG
was fully reproduced when testing the activation of primary human NK cells. Their broad antagonistic function towards
FccRIIIA, FccRIIA and FccRI activation was also recapitulated in a gain-of-function approach based on humanized
monoclonal antibodies (trastuzumab, rituximab) and isotypes of different IgG subclasses. Surface immune-precipitation
showed that both HCMV-encoded Fcc binding proteins have the capacity to bind trastuzumab antibody-HER2 antigen
complexes demonstrating simultaneous linkage of immune IgG with antigen and the HCMV inhibitors on the plasma
membrane. Our studies reveal a novel strategy by which viral FccRs can compete for immune complexes against various Fc
receptors on immune cells, dampening their activation and antiviral immunity.
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Introduction
Human cytomegalovirus (HCMV) constitutes the prototypical
human pathogenic b-herpesvirus found worldwide with high
immunoglobulin G (IgG) seroprevalence rates of 50–98% [1].
Despite the expression of a very large antigenic proteome of
approximately 750 translational products [2], HCMV avoids
sterile immunity and invariably persists lifelong in the human host
in a latent state with periodic phases of reactivation and virus
shedding. While infection of immune competent individuals is
usually subclinical, HCMV causes severe symptoms in immuno-
compromised individuals and congenitally infected newborns
[1,3]. Cytomegalovirus immune control is organized in a
hierarchical as well as redundant manner, with crucial roles for
natural killer (NK) cells as well as T lymphocytes [4]. HCMV
expresses a large set of immune evasion genes that impair
recognition of infected cells by CD8+, CD4+ and NK effector cells
and thus facilitate virus persistence, spread and superinfection [5–
7] while cellular immune responses are nevertheless indispensable
for CMV immune surveillance. Experimental and clinical
evidence suggest that cytomegalovirus can persist for the lifetime
by effectively defending itself from both cellular and humoral
immunity. In the absence of either viral immune evasion genes or
subsets of immune cells, the balance of pathogenesis versus
clearance of the virus can be tilted. For example, B cell deficient
mice exhibit a much higher susceptibility during recurrent mouse
cytomegalovirus (MCMV) infection compared to control mice,
reflected by 100–1,000-fold increased titers in the absence of
CMV-specific IgG [8]. Moreover, adoptive transfer of memory B
cells into naı¨ve Rag2/2 mice is sufficient for long term protection
from lethal MCMV disease [9], and passive immunization with
immune IgG reduces MCMV-induced pathology in newborn
mice [10]. In clinical settings, HCMV-immune IgG preparations
are used with varying degrees of success. Human intravenous
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hyperimmune immunoglobulin against HCMV (e.g. Cytotect)
significantly lowers the risk of congenital CMV infection and
disease at birth when given to primary HCMV-infected pregnant
women [11]. Nevertheless, meta-analyses of clinical studies with
solid organ transplant recipients as well as patients undergoing
hematopoietic stem cell transplantation document little if any
benefit of IgG prophylaxis against HCMV disease [12–14].
IgG antibodies have two functional domains: the fragment
antigen binding (Fab) that contains the paratope recognizing the
respective epitope of the antigen and the fragment crystallisable
(Fc) which recruits IgG effector functions. Receptors for the Fc
domain of IgG (FccRs) are expressed on immune cells to connect
the humoral and cellular branches of immunity. Upon IgG
binding and receptor activation, FccRs trigger a diversity of
effector responses including antibody-dependent cellular cytotox-
icity (ADCC), phagocytosis, endocytosis of immune complexes and
cytokine production. Importantly, the set of human FccRs
includes different activating members, i.e. FccRI (CD64),
FccRIIA (CD32A), FccRIIC (CD32C) and FccRIIIA (CD16)
which differ in immune cell distribution, affinity for distinct IgG
subclasses [15] and effector functions elicited upon activation [16–
19].
Fcc binding activity on the surface of HCMV-infected cells has
long been reported [20], but the consequences of Fcc binding to
immune responses are unknown [21]. The HCMV Fcc binding
proteins gp34 and gp68 are type I transmembrane glycoproteins
encoded by independent genes, RL11 and UL119-UL118,
respectively, which are fully dispensable for HCMV replication
in vitro [22,23]. Both HCMV proteins show cell surface disposition
and exquisite ligand specificity for human IgG but no other Ig
classes (e.g. IgA or IgM) [22]. Minimal sequence relatedness in
their extracellular domains with particular immunoglobulin
supergene family domains present in FccRI and FccRII/III
suggests differing binding characteristics from those of host FccRs
[22]. In contrast to host FccRs, both gp34 and gp68 recognize Fcc
in a manner independent of N-linked glycosylation, further
corroborating a binding mode to Fcc which is distinguishable
from host FccRs [24].
Cytomegaloviruses frequently reactivate and can super-infect
despite the presence of relatively high levels of HCMV-specific
IgG [25–27] which raises the apparent question by which
mechanism HCMV avoids antibody-mediated immune control.
One conceivable possibility is that HCMV-encoded FccRs gp34
and gp68 compete with cellular FccRs. To test this hypothesis, we
had to established a suitable FccR activation assay that allows a
comprehensive analysis of the activation status of individual FccRs
[28]. We compared cells infected with viruses lacking gp34 and/or
gp68 upon opsonization with graded doses of polyclonal HCMV-
immune IgG. As a control, we included the human a-herpesvirus
herpes simplex virus 1 (HSV-1), which expresses a viral FccR
composed of the glycoproteins gE and gI that is known to protect
infected cells from ADCC elicited by HSV-immune IgG [29,30].
Our approach identifies FccRI, FccRIIA and FccRIII as principal
targets of both HCMV gp34 and gp68, while the prototypic HSV-
1 FccR gE was found to inhibit only FccRIIA and FccRIII. This is
the first experimental proof of CMV-encoded glycoproteins
interfering with IgG-mediated immunity.
Results
HCMV and HSV-1 encoded viral FccRs (vFccRs) bind Fcc
on the surface of infected cells
To assess the relative surface density of viral Fcc receptors on
the plasma membrane of HSV and HCMV-infected cells, Fcc
binding was evaluated by flow cytometry using FITC-labeled Fcc
fragment. As expected, Fcc-FITC surface binding was observed
for HSV wt virus- and the gE revertant virus-infected cells, but not
for cells infected with DgE HSV (Figure 1A). MRC-5 cells
infected with either of two HCMV HB5 single vFccR deletion
mutants, HB5Dgp68 or HB5DIRLDgp34 [22], were decorated at
the cell surface with diminished levels of Fcc-FITC compared to
wt-infected control cells (Figure 1A). Cells infected with a
HCMV mutant lacking both gp68 and gp34 [31] showed only
very low Fc-binding when compared to mock-infected fibroblasts
(Figure 1A). Together with our previous experiments document-
ing Fcc binding upon ectopic expression of gp34 and gp68 using
recombinant vaccinia viruses (rVACV) [22] these data define gp34
and gp68 to be sufficient and essential for Fc binding by HCMV-
infected cells.
FccR activating IgG almost exclusively recognizes
antigens expressed during the late phase of HCMV
replication
In productively infected cells, herpesvirus gene expression is
regulated in a cascade fashion. Viral proteins encoded by genes of
the early phase of infection are required for viral DNA replication,
which is a prerequisite for the subsequent expression of structural
virion proteins during the late phase of gene expression. To assign
the immune-dominant HCMV and HSV surface antigens
recognized by opsonizing IgG to the temporal class of genes, we
applied the novel reporter cell system allowing quantification of
host FccR activation [28]. This assay is based on co-cultivation of
antigen-bearing cells with reporter cells stably expressing FccR-f
chain chimeric receptors which produce mouse IL-2 upon
recognition of immune IgG, provided that the opsonizing antibody
is able to activate the particular FccR [28]. Importantly,
BW5147:FccR-f reporter cells are neither activated by cells
lacking the appropriate antigen (e.g., non-infected cells) nor by
antigen-expressing cells which had been cultivated in absence of
IgG or in presence of non-immune IgG, proving strict antigen-
Author Summary
Herpes viruses persist lifelong continuously alternating
between latency and virus production and transmission.
The latter events occur despite the presence of immune
IgG antibodies. IgG acts by neutralization of virions and
activation of immune cells bearing one or more surface
receptors, called FccRs, recognizing the constant Fc
domain of IgG. Activating FccRs induce a wide range of
immune responses, including antibody dependent cellular
cytotoxicity (ADCC) of virus-infected cells by natural killer
(NK) cells, cytokine secretion and the uptake of immune
complexes to enhance antigen presentation to T cells. We
demonstrate that the HCMV glycoproteins RL11/gp34 and
UL119-118/gp68 block IgG-mediated activation of FccRs. A
novel reporter cell-based assay was used to test FccRs
individually and assess their relative susceptibility to each
antagonist. This approach revealed that gp34 and gp68
block triggering of activating FccRs, i.e. FccRI (CD64),
FccRII (CD32A) and FccRIII (CD16). Co-immunoprecipita-
tion showed the formation of ternary complexes contain-
ing IgG, IgG-bound antigen and the viral antagonists on
the cell surface. Assigning the redundant abilities of HCMV
to hinder IgG effector responses to the viral Fc binding
proteins, we discuss gp34 and gp68 as potential culprits
which might contribute to the limited efficacy of thera-
peutic IgG against HCMV.
Viral FccRs Inhibit Effector Cell Activation
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and immune IgG specificity of the assay (Figure S1 and
Reference [28]). Late phase gene expression was blocked using
250 mg/ml phosphonoacetic acid (PAA) which blocks the viral
DNA polymerase and is the active component of the clinically
approved anti-HCMV drug Foscarnet. At 72 and 48 hpi, resp.,
infected cells were opsonized with graded concentrations of
intravenous immunoglobulin (IVIG) Cytotect as a source of
human HCMV- and HSV-immune IgG. As expected, immune
IgG did not induce receptor activation (IL-2 response) in the
presence of mock-infected cells (Figure 1B). While late antigens
of HCMV efficiently triggered FccRIII reporter cells, infected cells
arrested in the early phase of replication elicited very poor if any
responses (Figure 1B). On the contrary, early antigens of HSV-1
were sufficient to efficiently trigger FccRIII and HSV late antigens
Figure 1. Viral FccRs bind Fcc on the cell surface and opsonizing IgG dependent FccR activation is restricted to the late phase of
HCMV but not HSV replication. (A) MRC-5 cells were infected with 2 PFU/cell for 72 hpi with HCMV HB5 wildtype, HB5Dgp68, HB5DIRLDgp34 or
HB5DIRLDgp68/Dgp34 (left) or 24 hpi with HSV-1 (right). Cells were resuspended with PBS/2% (vol/vol) FCS containing 2 mM EDTA, stained with
hFcc-FITC and measured in a FACS Canto II. Dead cells were excluded by PI or DAPI-staining. (B) MRC-5 cells were infected with 2–3 PFU/cell of HCMV
HB5 wt or (C) HSV-1 strain F. After centrifugation enhancement of infection, cells were incubated 3 h at 37uC at 5% CO2. After washing once, PAA
(250 mg/ml) in D-MEM 10% (vol/vol) FCS was added. 48 hpi for HSV or 72 hpi for HCMV, cells were opsonized with grading dilutions of Cytotect for
30 minutes, washed twice with D-MEM 10% (vol/vol) FCS and co-cultivated with 16105 BW:FccR-f reporter cells per well. Measurement of mIL-2 in
supernatants after 16 h of co-cultivation of reporter cells with targets was performed by ELISA. Values are presented in the graphic as OD 450 nm. 3
independent wells were measured, means are shown with standard deviations (error bars) for 2 independent experiments. Significance of results
(Student’s t-test) is presented in Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
doi:10.1371/journal.ppat.1004131.g001
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only slightly increased FccR-f activation (Figure 1C). Despite the
fact that Cytotect is prepared from donors selected for particularly
high HCMV IgG titers [11,32] we found - in agreement with
earlier studies [28] - that Cytotect contains higher titers of HSV-
immune IgG activating FccRIII compared to FccRIII-reactive
HCMV-immune IgG. Due to this fact, IVIG dilutions used for
HSV-1 and HCMV experiments had to be chosen differently. The
relatively poor responses triggered by IgG opsonized HCMV-
infected cells was compatible with our hypothesis that HCMV
could be able to reduce the activation of FccRIII by immune IgG,
and that vFccR gp68 and gp34 might represent candidates for
such inhibition.
Interference with host FccR activation by HSV-1 gE,
HCMV gp68 and HCMV gp34
To test the conjecture that vFccR gp68 and gp34 could prevent
host FccR activation by HCMV IgG, we pursued the
BW5147:FccR-f reporter cell approach. To assess if and to what
degree viral FccRs can interfere with host FccRs activation, we
first compared responses of FccRIII reporter cells co-cultured with
IgG-opsonized HSV-1 wt infected vs. HSV-1 DgE-infected MRC-
5 cells (Figure 2A). Inhibition of ADCC by PBMCs was reported
to be a function of the prototypic HSV-1 FccR gE [30], albeit the
specific host FccRs which are blocked by gE have not been
elucidated yet. As before (Figure 1C), we observed a dose-
dependent activation of the reporter cells upon co-cultivation with
HSV-1-infected cells but not with mock infected cells. The DgE
HSV-1 mutant led to an increased activation of FccRIIIA upon
opsonization of target cells with Cytotect, in accordance with
published data [29,30]. The same type of result was obtained
when using BW5147:FccRIIA-f reporter cells, indicating that gE
also antagonizes activation of this host Fcc receptor. Surprisingly,
gE enhanced, rather than inhibited the IgG-dependent activation
as deduced from the overall superior activation of the chimeric
FccRI-f by wt HSV-1 when compared to HSV-1 DgE
(Figure 2A).
The results of HSV-1 gE encouraged us to subsequently test
HCMV HB5Dgp68 and HB5DIRLDgp34 mutants using the same
experimental strategy. MRC-5 fibroblasts were left uninfected or
infected with wt-HCMV strain HB5 versus HB5Dgp68
(Figure 2B), or with HB5DIRL (the parental virus of the
following mutants) versus HB5DIRLDgp34 and HB5DIRLDgp68/
Dgp34, resp., a double mutant lacking both gp68 and gp34
(Figure 2C). 72 h post HCMV infection, target cells were
incubated with graded dilutions of Cytotect before BW:FccRIIIA-
f responder cells were added. HB5Dgp68 induced a clearly higher
response over an extended range of IgG dilutions compared to wt-
HCMV HB5 infected cells. Likewise, HB5DIRLDgp34-opsonized
cells induced clearly higher reporter cell responses compared with
HB5DIRL opsonized targets, while HB5DIRLDgp68/Dgp34
exhibited only marginal further increase of the response
(Figure 2C). These results suggested that cells infected with virus
mutants lacking viral Fc-binding proteins elicit exaggerated
activation of FccRIIIA, provided that the amount of opsonizable
HCMV antigens is indeed comparable between the viruses
analyzed. To verify this supposition, cells were labelled with
F(ab)2 antibody fragments prepared from Cytotect and analysed
by FACS. As shown in Figure S2, cells infected with HCMV
mutants lacking gp34 and/or gp68 did not show higher levels of
opsonizing antigens on the plasma membrane. To compare the
relative impact of gp68 versus gp34 on FccRIII activation with a
higher degree of accuracy, i.e. in the context of an identical
HCMV genome possessing a preserved UL/b9 gene region,
another set of targeted vFccR gene deletions was constructed
based on the AD169varL derived BACmid pAD169 which carries
unlike pHB5 only a single copy of TRL genes including TRL11
[33]. As demonstrated in Figure 2D, targeted deletion of UL119-
118/gp68 and TRL11/gp34 reproduced the increased activation
of BW:FccRIIIA-f responder cells, while combined deletion of
both vFccRs only marginally enhanced the response further. Next
we determined if gp34 and gp68 could affect further activating
host FccRs and performed co-cultivation assays with MCR-5 cells
infected with the same panels of HCMV mutants after opsoniza-
tion with Cytotect and incubated with BW:FccRIIA-f and
BW:FccRI-f reporter cells (Figure 2C–D). While deletion of
both HCMV Fcc-binding proteins resulted in significantly
enhanced responses by both FccRIIA and FccRI, the isolated
removal of gp68 resulted in a slightly more drastic phenotype with
regard to BW:FccRIIA-f activation (Figure 2D). Notably,
combined removal of gp34 and gp68 led to a Dgp34-like
phenotype, contrasting to the additive effect seen with FccRIII
at low IgG concentrations. In conclusion, the data suggested that
both of the HCMV-encoded FccRs might have developed the
ability to interfere with the activation of FccRIII, FccRIIA and
FccRI, while HSV gE blocks FccRIII and FccRIIA but fails to
inhibit FccRI activation.
UL118-119 and RL11 gene reversion restore resistance to
FccR activation by immune IgG
To exclude the possibility that second site mutations which
occurred during the BACmid mutagenesis procedure are respon-
sible for the observed loss of HCMV-mediated inhibition of host
FccR activation by immune IgG, an entirely independent panel of
virus deletion mutants and the appropriate rescued versions were
generated. The mutants were constructed using the HCMV
TB40/E-derived BACmid [34] taking advantage of i) a single gene
copy of RL11 coding for gp34, ii) a complete HCMV ULb9 gene
region lacking in HCMV HB5 but present in HCMV clinical
isolates and iii) a technically more feasible re-insertion strategy of
the vFccR coding genes. MRC-5 fibroblasts were left uninfected
or infected with the HCMV TB40/E wt expressing gp68 and
gp34, or with gp68 and gp34 single gene deletion mutants, resp.,
or independent single gene revertant mutants expressing gp68 or
gp34. Using BW:FccRIIIA-f responder cells and graded concen-
trations of HCMV immune IVIG, the gp34 and gp68 TB40/E
deficient mutants elicited a stronger FccR-f activation response
than the TB40/E wt (Figure S3A), while the density of
opsonizing cell surface antigens was not altered (Figure S3B).
The finding that three independent virus mutants lacking Fc
binding proteins show congruent phenotypes makes unintended
second site mutations as cause for the effect highly unlikely.
Nevertheless, revertant viruses were assessed. As expected, both of
the revertant viruses exhibited a wt-like phenotype (Figure S3A).
In comparison to HCMV HB5, HCMV TB40/E shows a more
protracted replication kinetic. Consistently, we observed more
efficient IgG-dependent activation of FccRIIIA-f at 96 hpi
compared with 72 hpi. Therefore, HCMV TB40/E-based assays
were performed 96 h post infection. The HCMV TB40/E results
confirmed that both HCMV-encoded FccRs inhibit the activation
of FccRIIIA and that their reinsertion into the virus genome
reestablishes the vFccR inhibition phenotype.
Inhibition of IgG1 (trastuzumab) mediated activation of
FccRs
To test if gp34 and gp68 suffice to impair IgG-dependent
activation of FccRs, two factors of our experimental approach were
modified: (i) gp34 and gp68 were expressed outside the context of
Viral FccRs Inhibit Effector Cell Activation
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Figure 2. HSV-1 gE, HCMV gp68 and HCMV gp34 interfere with host FccR activation upon opsonization of cells with polyclonal
immune IgG. (A) The HSV vFccR gE inhibits FccRIIIA and FccRIIA activation but fails to inhibit FccRI. Human MRC-5 fibroblasts were infected with 2
PFU/cell of HSV-1 strain F wt and DgE for 24 h. Cells were opsonized with Cytotect at different concentrations for 30 min. After removing of unbound
antibodies with D-MEM 10% (vol/vol) FCS, 16105 BW:FccR-f transfectants per well were added and co-cultivated overnight. BW:FccR activation was
determined by measuring mIL-2 by ELISA. Three independent replicates were measured; means with standard deviations (error bars) are shown for 4
independent experiments. (B) HCMV vFccR gp68 interferes with FccRIIIA, FccRIIA and FccRI activation. MRC-5 cells were infected with HCMV HB5 wt
virus or HB5Dgp68 (2 PFU/cell) for 72 h. Fibroblasts were opsonized with Cytotect at different concentrations for 30 min. After removing of unbound
antibodies by washing, 16105 BW:FccR-f transfectants were added per well. Measurement of mIL-2 in supernatants after 16 h of co-cultivation of
Viral FccRs Inhibit Effector Cell Activation
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HCMV infection by recombinant vaccinia viruses, and (ii) instead of
polyclonal HCMV IVIG, a well-defined humanized therapeutic
monoclonal IgG1 antibody (trastuzumab) was used as an activator
of host FccRs upon binding to its antigen HER2. rVACV
expressing HSV gE-infected HER2 antigen positive SKOV-3
tumor cells were opsonized with graded concentrations of
trastuzumab recognizing HER2 and compared with wt-VACV as
well as mock-infected cells. The opsonized target cells were co-
cultured with the panel of FccR reporter cells (Figure 3A).
Opsonized VACV-infected cells exhibited a reduced capacity to
trigger FccRIIIA in comparison to mock cells, most likely due to the
protein host shut-off function of VACV. Importantly, trastuzumab-
mediated FccRIIIA triggering was further impaired by rVACV gE,
providing proof of principle that ectopically expressed gE suffices to
interfere with IgG1-dependent FccRIII activation. In contrast to
FccRIII, trastuzumab reproducibly failed to induce FccRII
responses (Figure 3A). When trastuzumab-opsonized cells were
probed with FccRI transfectants, the presence of gE did not
attenuate but rather enhanced the response (Figure 3A), confirm-
ing the unexpected phenotype in the HSV-infected cell setting
observed before (Figure 2A). Next, rVACVs were used to express
gp34 and gp68 ectopically in HER2 positive SKOV-3 targets which
were opsonized with different concentrations of trastuzumab before
co-culture with the same panel of responder cells as already
described (Figure 3B). Both gp34 as well as gp68 significantly
reduced activation of FccRIII and FccRI, albeit in this setting gp34
seemed slightly more potent than gp68. In summary, deploying a
gain-of-function approach and using a monoclonal human IgG1,
the results verified that both HCMV FccRs are sufficient to prevent
the activation of FccRI and FccRIII.
Interference with host FccRIIA activation by ectopic
expression of herpesviral FccRs
Trastuzumab is not capable to activate FccRIIA (see above,
Figure 3A–B). Nevertheless, we wished to assess the effect of
ectopically expressed vFccRs on FccRIIA activation. Therefore, in
a further approach CD20 transfected 293T cells [35] were infected
with rVACV expressing gE, gp68 or gp34 before opsonized with
rituximab another well-defined humanized therapeutic monoclo-
nal IgG1 antibody (Figure S4A and S4B). All vFccRs inhibited
FccRIIA activation verifying that ectopic expression of the viral
Fcc binding proteins gE, gp34 and gp68 hinder the activation of
the host FccRIIA in a gain-of-function approach.
FccRIII inhibition by gp34 and gp68 across IgG subclasses
Humans respond to HCMV infection with the production of
IgG1 which is the immunodominant subclass, followed by IgG3,
reporter cells with targets was performed by ELISA. Values are presented in the graphic as OD 450 nm. Three independent wells were measured;
means with standard deviations (error bars) are shown for 4 independent experiments. Significance of results (Student’s t-test) are presented in Table
S1 as *: p,0.05 **: p,0.01 ***: p,0.001. (C) HCMV vFccR gp34 interferes with FccRIIIA, FccRIIA and FccRI activation. As in (B) but MRC-5 cells were
infected with HCMV HB5DIRL, HB5DIRLDgp34 or HB5DIRLDgp68/Dgp34 (2 PFU/cell) for 72 h. (D) gp34 and gp68 interfere with FccR activation in
AD169varL infected cells. As in (B) but MRC-5 cells were infected with AD169varL wt, AD169varLDgp68, AD169varLDgp34 or AD169varLDgp68/
Dgp34.
doi:10.1371/journal.ppat.1004131.g002
Figure 3. Ectopic expression of HSV-1 gE, HCMV gp68 and HCMV gp34 inhibit IgG1 (trastuzumab) mediated activation of FccRs. (A)
SKOV-3 cells were infected for 24 h with 2 PFU/cell VACV wt and rVACV expressing gE or (B) rVACV expressing gp68 or gp34 before opsonized with
trastuzumab at different concentrations for 30 min. After removing of unbound antibodies by repeated washing with D-MEM 10% (vol/vol) FCS,
16105 BW:FccR-f transfectants per well were added and co-cultivated overnight. BW:FccR-f activation was determined by measuring mIL-2 by ELISA.
Three independent replicates were measured, means with standard deviations (error bars) are shown for 3 independent experiments. Significance of
results (Student’s t-test) are presented in Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
doi:10.1371/journal.ppat.1004131.g003
Viral FccRs Inhibit Effector Cell Activation
PLOS Pathogens | www.plospathogens.org 6 May 2014 | Volume 10 | Issue 5 | e1004131
while HCMV-immune IgG2 and IgG4 is detected only at very low
levels if produced at all [36,37]. In contrast to HSV-1 gE, HCMV
gp68 and gp34 bind monomeric IgG of all human subclasses, i.e.
IgG1, IgG2, IgG3, and IgG4 [22], whereas gE does not bind IgG3
[38,39]. To assess whether HCMV gp68 and gp34 can inhibit
FccRIIIA/CD16 activation through immune complexes formed
by different IgG isotypes, we took advantage of a panel of
rituximab-derived isotypic IgG antibodies. CD20 transfected
293T target cells [35] were infected with VACV wt or rVACV
expressing gp68, gp34 or MULT-1 as a negative control and
opsonized with anti-hCD20 IgG isotypes including an IgA
constant region fused to the variable region of rituximab as an
antibody control. CD20 expression revealed very similar levels of
antigen expression on the cell surface of VACV target cells (data
not shown). While opsonized IgG1 and IgG3 isotypes efficiently
activated FccRIIIA, very little to no activation was observed with
IgG2, IgG4 and IgA, confirming previous data [28]. Both gp34 as
well as gp68 strongly reduced activation of FccRIIIA by IgG1 and
IgG3 (Figure 4). The data documented the inhibitory potency of
both HCMV FccRs against IgG1 and IgG3-formed immune
complexes and confirmed the functional distinction of gp34 and
gp68 against HSV gE.
The herpesviral FccRs inhibit antibody dependent NK cell
degranulation
CD16/FccRIII is an essential IgG receptor for activation of NK
cells mediating ADCC responses [40,41] but also found on human
cd T cells induced by HCMV infection [42]. The data obtained
with the FccRIII-f reporter cells strongly suggested that gp34, gp68
as well as HSV-1 gE operate as inhibitors of FccRIII/CD16+ NK
cells since BW:FccRIII-f responses showed an excellent match with
CD107a mobilization of primary human NK cells upon CD16/
FccRIII cross-linking [28]. Therefore, we tested the activation of
primary human NK cells by fibroblasts infected with HSV-1,
HCMV and mutants devoid of viral Fcc binding proteins,
respectively, in the presence of virus-immune opsonizing IgG in a
CD107a degranulation assay [43]. The sources of the opsonizing
IgG were sera donated by HSV/HCMV-seropositive donors
(Figure 5A and Figure 5B, resp.) or Cytotect (Figure 5C).
rhIL-2 overnight preactivated NK cells from HSV/HCMV sero-
negative donors were enriched by negative selection and analyzed
after 4 hours of co-incubation with infected cells opsonized with
graded concentrations of immune IgG. HCMV encodes numerous
inhibitors of NK cell activation [44,45]. To focus on IgG-dependent
NK cell activation, NK activation was calculated and depicted as
percentage of IgG-specific CD107a mobilization (i.e. percentage of
CD107a-positive cells obtained with the immune antibody opson-
izing target cells minus the percentage of CD107a-positive cells
obtained with non-immune antibody treated target cells). A higher
ratio of IgG-dependent CD107a positive cells in the case of HSV-1
DgE-infected cells compared with wt HSV-1 infected cells was
observed (Figure 5A). Likewise, the HB5Dgp68, HB5DIRLDgp34
and HB5DIRLDgp68/Dgp34 HCMV mutants yielded clearly
increased IgG-dependent CD107a mobilization as HCMV HB5
(Figure 5B). As observed with BW:FccR-f responder cells, gp34
and gp68 inhibited FccRIIIA NK activation independently, but no
additive effects were noted upon deletion of both vFccRs. To
exclude donor-specific effects, NK cells from six different donors
were analyzed in degranulation assays comparing HCMV HB5 wt
with HB5DIRLDgp68/Dgp34 -infected targets opsonized with
Cytotect as a source of immune IgG and non-immune sera as a
negative control. All donors showed a higher percentage of IgG-
dependent CD107a positive cells in the case of HB5DIRLDgp68/
Dgp34 -infected cells (Figure 5C). Taken together, these data
demonstrated that vFccR gE, gp34 and gp68 on the surface of
infected cells mediate inhibition of IgG-dependent NK cell
degranulation.
HCMV FccRs form ternary complexes with antigen and
IgG on the cell surface compatible with antibody bipolar
bridging
HCMV gp68 was found to bind the Fc CH2-CH3 interface of
monomeric IgG at nanomolar affinity [24]. To get insight into the
intermolecular interactions underlying the inhibitory function of
gp34 and gp68 when blocking antigen-antibody complexes, we
tested the occurrence of a physical complex on the surface of cells
consisting of the target antigen, bound IgG and each of the
HCMV FccRs. We took advantage of immune complexes
(composed of trastuzumab and its antigen HER2) which were
shown to be sensitive to the blockade through gp34 and gp68
when activating FccRIII and FccRI (Figure 3B). HER2-
expressing SKOV-3 cells were infected with rVACV expressing
Flag-tagged gp34, gp68 or a control protein, DIg1-m138, a non-
functional MCMV m138/fcr-1 truncation mutant [46] and
opsonized with trastuzumab (‘T’) or with an IgG1 isotype control
antibody, palivizumab (‘P’) (see sketch in Figure 6A). VACV-
infected cells were thoroughly washed to remove unbound
antibodies and subsequently lysed. To exclude Fcc-mediated
binding of vFccRs through anti-Flag antibodies, vFccR proteins
were immunoprecipitated using a-Flag F(ab)2-coupled agarose
beads. The precipitated proteins were separated by SDS-PAGE
and analyzed by immunoblotting using an HER2 specific antibody
(Figure 6B). An anti-human IgG-specific antibody was used to
detect the co-precipitated antibody. An immuno blot confirmed
expression and immunoprecipitation of the vFccRs. Retrieval of
palivizumab by gp34 and gp68 was weaker than retrieval of
trastuzumab. This difference could be explained by the fact that
trastuzumab could be retained by the cells via vFccRs and via
HER2, while palivizumab could only be retained by vFccRs.
Subsequently, gp34 and gp68 retrieved trastuzumab antibodies
bound to HER2 during lysis and precipitation. Nevertheless, co-
precipitation of human HER2 molecules occurred only in the
presence of specific antibody trastuzumab and the HCMV FccRs
but not in the negative control DIg1-m138 (Figure 6B, lanes 5,
Figure 4. HCMV gp68 and gp34 inhibit FccRIII activation by
rituximab antibody isotypes. CD20 transfected 293T cells were
infected for 16 h with 2 PFU/cell of VACV wt or rVACV expressing gp68,
gp34 or MULT-1 as a control. After opsonization with 1 mg/ml of each
antibody isotype for 30 min. and removing of unbound antibody by
washing, cells were co-cultivated with 16105 BW:FccRIIIA-f reporter
cells per well for 16 h before supernatants were collected and mIL-2
was determined by ELISA. Each value represents three replicates; means
with standard deviations (error bars) are shown for 2 independent
experiments. Significance of results (Student’s t-test) are presented in
Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
doi:10.1371/journal.ppat.1004131.g004
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Figure 5. The presence of the vFccRs on the surface of infected cells inhibits antibody dependent NK cell degranulation. (A) MRC-5
fibroblasts were infected with HSV-1F wt, DgE and DgE revertant for 24 h before cells were opsonized with HSV IgG positive and negative human
sera. After 30 min of incubation, unbound antibodies were washed away and NK cells at an E:T ratio of 10:1 were added. After 4 h, CD107a surface
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7 and 3, respectively). Binding of human IgG antibodies,
trastuzumab and the isotype control antibody palivizumab, was
observed to both vFccRs (Figure 6B, lanes 5, 6, 7 and 8). No
binding of trastuzumab or palivizumab was detectable to the DIg1-
m138- Flag protein (Figure 6B, lanes 3 and 4). Taken together,
the ability of cell surface resident vFccRs gp34 and gp68 to bind to
IgG immune complexes was demonstrated. This finding is
compatible with the model of ‘‘antibody bipolar bridging’’
described for the HSV-1 FccR gE [47–49]. According to this
concept, epitope-bound IgG on the surface of a virus-infected cell
is simultaneously sequestered by the gE:gI complex via its Fc
domain, thus preventing the activation of immune effector
molecules via host FccRs.
Soluble ectodomains of HCMV vFccRs inhibit IgG-
dependent host FccRs activation
Soluble truncation versions of HSV-1 gE and HCMV gp68
were instrumental to unravel structural requirements and stoichi-
ometry of herpesviral FccRs forming complexes with Fcc
[24,49,50]. To test whether membrane insertion of gp34 and
expression on the NK cells was measured in FACS. Percentage of IgG-specific degranulation CD107a-positive cells = (% of CD107a-positive cells with
the immune antibody opsonization - % of CD107a-positive cells with non-immune antibody). (B) MRC-5 fibroblasts were infected with HCMV HB5 wt,
HB5Dgp68, HB5DIRLDgp34 and HB5DIRLDgp68/Dgp34 for 72 h before cells were opsonized with HCMV IgG positive and negative human sera. After
30 min of incubation, unbound antibodies were washed away and NK cells at an E:T ratio of 10:1 were added. After 4 h, CD107a surface expression
on the NK cells was measured in FACS. Percentage of IgG-specific degranulation CD107a-positive cells = (% of CD107a-positive cells with the immune
antibody opsonization - % of CD107a-positive cells with non-immune antibody) (C) MRC-5 fibroblasts were infected with HCMV HB5 wt and
HB5DIRLDgp68/Dgp34 for 72 h before opsonized with Cytotect or human HCMV-IgG negative sera at 1:10 and 1:100 dilutions. After 30 min of
incubation, unbound antibodies were washed away and NK cells from six different donors at an E:T ratio of 10:1 were added. After 4 h, CD107a
surface expression on the NK cells against HCMV-infected cells was measured. Percentage of IgG-specific degranulation CD107a-positive cells = (% of
CD107a positive cells with the immune antibody opsonization - % of CD107a positive cells with non-immune antibody). Single measurements of
CD107a cells are shown. One of three (A, B) or two (C) representative experiments is shown.
doi:10.1371/journal.ppat.1004131.g005
Figure 6. The HCMV vFccRs gp68 and gp34 bind antigen-IgG complexes. (A) Schematic representation of the ‘antibody bipolar bridging’
model. (B) Lysates of SKOV-3 cells containing the heterocomplex of vFccR-FLAG, antibody and antigen are immunoprecipitated using an anti-FLAG
agarose. SKOV-3 cells expressing HER2 antigen on the surface were infected with rVACV expressing the vFccRs before opsonized with the
trastuzumab antibody (bipolar bridging-antibody) (T) or an isotype control IgG1 antibody, palivizumab (P). Lysates were prepared after incubation of
infected cells with antibody. An anti-Flag agarose IP was performed and retrieved antigens were detected in western blot with anti-ErbB2-specific
mAb recognizing human HER2, anti-human IgG, and anti-Flag (M2, Sigma-Aldrich) detecting the Flag-tagged vFccRs. Equal expression of HER2 in cell
lysates was verified by western blot analysis with an anti-ErbB2-specific rabbit mAb which detects human HER2 (bottom).
doi:10.1371/journal.ppat.1004131.g006
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gp68 is required to interfere with the activation of host FccRs,
recombinant C-terminally truncated ectodomains of HCMV
FccRs were generated and purified from supernatants of
transfected human 293 cells. To evaluate if soluble gp34 (sgp34)
and soluble gp68 (sgp68) are sufficient to block triggering of host
Fcc receptors, HER2-positive cells were opsonized with trastuzu-
mab and different amounts of recombinant soluble vFccRs were
concomitantly added to BW:FccRIIIA-f cells (Figure 7A) or
BW:FccRI-f cells (Figure 7B). Soluble ICOS ligand (sICOSL)
served as a negative control protein. Both sgp34 and sgp68 were
able to inhibit activation of the reporter cells expressing FccRIIIA,
although clear differences in concentration dependency between
soluble vFccRs were observed. In contrast to full-length HCMV
FccRs, sgp34 was more potent against FccRIIIA compared to
sgp68, since trace amounts of sgp34 hardly detectable in western
blot (Figure S5) were sufficient for significant inhibition. In the
case of FccRI, sgp68 was not significantly reducing its activation
by trastuzumab, suggesting the specific requirement of the gp68
transmembrane domain for effective inhibition of FccRI/CD64.
To extend the data to HCMV infection and to test
BW:FccRIIA-f cells, a polyclonal antibody preparation (IVIG,
Cytotect) was used to opsonize MRC-5 fibroblasts infected with
the HCMV HB5DIRLDgp68/Dgp34 mutant lacking both gp68
and gp34. Using BW:FccRIIIA-f reporter cells, both of the soluble
HCMV vFccRs prevented activation when compared with
treatment of cells with the sICOSL control (Figure 7C).
Moreover, this approach allowed to test activation of
BW:FccRIIA-f cells which did not respond to trastuzumab (see
Figure 3). As depicted in Figure 7D, FccRII responses were also
sensitive to sgp34 and, to a lesser extent, sgp68. These results
provide proof of principle that soluble HCMV FccRs retain FccR
blocking abilities, and that sgp34 is particularly efficient.
Soluble ectodomains of HCMV vFccRs inhibit IgG-
dependent NK cell degranulation
In an attempt to extend the previously made observation of
sgp34 and sgp68-mediated inhibition of IgG-triggered FccRIII/
CD16+ BW5147 responder cells to primary human NK cells,
purified IVIG Cytotect was coated directly to a plate serving as a
source of ‘immune-complexed’ IgG. After blocking with D-MEM
10% FCS (vol/vol), soluble proteins, IL-2 pre-activated primary
NK cells and a-CD107a-PECy5 antibody were added. Soluble
ICOS ligand (sICOSL) served as a negative control protein. In the
absence of coated IgG, only 10% of NK cells responded with
CD107a mobilization, while in the presence of coated IgG more
than 70% of NK cells translocated CD107a to the cell surface
(Figure 8A), confirming the IgG-dependency of the elicited NK
cell response. Importantly, both sgp34 and sgp68 were able to
Figure 7. Soluble ectodomains of HCMV vFccRs interfere with FccR activation. (A) SKOV-3 cells were opsonized with 100 ng/ml
trastuzumab for 30 minutes and washed three times with D-MEM 10% FCS (vol/vol) before soluble proteins were added in graded concentrations
concomitantly with BW:FccRIIIA-f transfectants. mIL-2 was determined in supernatants (which were harvested after 16 h of co-cultivation of
responder cells with target cells) by ELISA. (B) As in (A) but SKOV-3 cells were opsonized with 500 mg/ml trastuzumab for 30 minutes and washed
three times with D-MEM 10% FCS (vol/vol) before soluble proteins were added in graded concentrations concomitantly with BW:FccRI-f cells. (C)
MRC-5 cells were infected with HCMV HB5DIRLDgp68/Dgp34 (2 PFU/cell) for 72 h before soluble proteins were added in graded concentrations
concomitantly with BW:FccRIIIA-f responder cells. MRC-5 fibroblasts were opsonized with 1:50 diluted Cytotect for 30 min. After removing of
unbound antibodies by washing, soluble proteins and BW:FccR-f transfectants were added and co-cultivated overnight. (D) as in (C), but HCMV
HB5DIRLDgp68/Dgp34 infected target cells were opsonized with 1:10 diluted Cytotect and BW:FccRIIA-f cells were used as responders. n = 3
replicates, means with standard deviations (error bars) are shown for 2 independent experiments. Significance of results (Student’s t-test) are
presented in Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
doi:10.1371/journal.ppat.1004131.g007
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inhibit IgG-dependent NK degranulation, although a clear
difference in the concentration dependency between soluble
vFccRs was observed. Consistent with the results received with
BW:FccRIIIA-f reporter cells (Figure 7C), sgp34 was more
potent against IgG-dependent NK activation compared to sgp68,
since trace amounts of sgp34 (Figure 8B) were sufficient to
significantly interfere with degranulation of NK cells. Using a gain
of function approach the data confirmed the inhibitory capacity of
gp34 and gp68 to attenuate IgG-mediated NK cell activation.
Discussion
Here we identified various members of the human FccR family,
i.e. FccRI/CD64, FccRII/CD32A and FccRIII/CD16A, to be
targeted by the HCMV FccRs gp34 and gp68 which act as
antagonists of ligand induced FccR responses. This ability enables
HCMV to evade from IgG effector responses and should have
direct proviral effects in scenarios of post-acute and recurrent
infection when glycoprotein-specific IgG antibodies are synthe-
sized [51]. Several independent experimental approaches support
this conclusion: i) HCMV HB5-derived mutants with deletions of
the gp34 and gp68 coding genes, TRL11/IRL11 and UL118-119,
respectively, showed significantly increased activation of host
FccRs upon opsonization of infected cells with polyclonal HCMV
immune IgG using different types of responder cells (i.e. BW5147
transfectants expressing FccR-f chain chimeras and primary
human NK cells); ii) this HCMV phenotype was reproduced with
targeted RL11 and UL118-119 mutants of the AD169varL and
TB40/E strain and iii) fully reversed by retransfer of the
responsible genes into the RL11- and UL118-119-deficient
TB40/E genomes; iv) a gain-of-function approach based on
ectopic VACV-based expression of gp34 and gp68 which allowed
functional analysis of well characterized therapeutic human
monoclonal antibodies and different IgG isotypes thereof and v)
functional testing of recombinant soluble ectodomains of both
HCMV inhibitors using BW5147:FccR reporter cells as well as
primary human NK cells. Importantly, the inhibitory effect of
gp34 and gp68 was demonstrated at physiological concentrations
of polyclonal HCMV immune IgG, i.e. within an extended
concentration range of human serum and ten to fifty fold lower.
The quite complex and overlapping expression patterns of host
Fc-IgG receptors on a multitude of diverse human immune cell
(sub-)populations [17] have obstructed a systematic functional
analysis of individual host FccRs which differ with respect to
molecular and functional features including the composition of
their ectodomain, intracellular signaling and IgG subclass prefer-
ences. Only a recently developed methodologically broadly tested
and proven reporter cell assay [28] enabled a comprehensive and
quantitative functional assessment of potential viral antagonists
and their relative effectiveness against distinct host FccRs. The
new methodology was complemented and validated by immuno-
logical as well as biochemical assays, i.e. the use of primary human
NK cells as natural responder cells and immunoprecipitation
studies, the results of which accord very well with the findings
Figure 8. Soluble ectodomains of HCMV vFccR interfere with antibody dependent NK cell degranulation. (A) Cytotect was coated to a
plate in binding buffer (0.1 M Na2HPO4 pH 9.0) at a concentration of 0.5 mg/ml and incubated for 2.5 hours at 37uC. After blocking for 30 minutes
and washing unbound antibodies, soluble proteins, rIL-2 pre-activated primary NK cells and a-CD107a-PECy5 antibody were added and incubated for
4 hours at 37uC. Duplicates were measured for CD107a surface expression after dead cell exclusion with DAPI staining in a FACS Canto II. Means are
shown with standard deviations (error bars). Significance of results (Student’s t-test) are presented in Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
(B) To compare the amounts of soluble proteins used in (A), SDS-PAGE and anti-V5 immunobotting was performed.
doi:10.1371/journal.ppat.1004131.g008
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made with the BW5147:FccR-f test system. Last but not least, the
well-known viral FccR inhibitor, HSV gE, was included as an
internal control. Previous publications reported inhibition of
ADCC, virion neutralization and complement mediated virolysis
by HSV gE [47,52,53]. Since the blockade of ADCC by gE was
not yet attributed to a specific host FccR [30,47,54], analysis of the
relative impact of HSV gE on distinct host FccRs represents a
novel aspect of our study. On the basis of the test performance of
HSV gE, both gp34 and gp68 demonstrated an at least equivalent
if not superior efficacy to block FccRIII and FccRIIA mediated
responses. Surprisingly and contrasting with both HCMV vFccRs,
gE enhanced rather than attenuated FccRI activation. This
observation warrants further studies how HSV-infected cells affect
FccRI bearing immune cells like monocytes, macrophages, DCs
and neutrophils in the presence of HSV-immune IgG.
Structural requirements for FccR inhibition
The inhibition mechanism of IgG-mediated effector functions
by gE has been suggested to involve ‘antibody bipolar bridging’
[47]. Pioneering studies of the Bjorkman laboratory demonstrated
that the architecture of the gE/gI-IgG complex allows antibody
bipolar bridging [49], whereby the gE binding site for Fcc does not
directly overlap with the binding sites to the host FccRs or the C1q
component of complement, which both bind to the upper hinge
region of IgG or near the CH2 domain [55,56]. Therefore, the
structure of the gE/gI-Fc complex does not directly explain how
gE binding to the Fc region of IgG leads to evasion from FccR-
and complement-mediated immune responses. Our biochemical
data reveal formation of ternary heterocomplexes composed of
antigen, IgG and gp34/gp68, i.e. a molecular configuration
compatible with the minimal requirements of the concept of
‘bipolar bridging’ [47,49]. The observation that soluble gp34 and
gp68 remain potent inhibitors of FccR activation demonstrates
that the functional inactivation of the host FccR on the responder
cell does not require fixation of the opsonized IgG to the plasma
membrane as insinuated by the classical concept of bipolar
bridging. Although there is no crystal structure available for any
HCMV vFccR, detailed biochemical evidence was generated of
how HCMV FccRs recognize Fcc, particularly for gp68. The
gp68 Fcc binding site was mapped to the CH2-CH3 interface
region of Fcc [24] which is remote from the FccRII/III contact
site, that involves the hinge between the Fcc and Fab domains
including the upper portion of the CH2 domain [55,57].
Specifically, gp68 binding to Fcc is affected by mutations at the
CH2-CH3 domain interface of IgG, mapping its binding site to
determinants situated nearby but not identical with those that are
recognized by gE [24]. We observed robust functional differences
between HSV-1 gE and HCMV gp68 in their manipulation of
FccRI, further substantiating the mechanistic differences between
these viral inhibitors regarding their interaction mode with Fcc.
While the binding of IgG by gE must induce conformational
changes of the antibody that result in an enhancement of FccRI
activation, gp68 binding to IgG induces the opposite effect. Since
both gE and gp68 had concordant inhibitory effects on FccRIII,
our data further imply that FccRI and FccRIII must bind IgG in a
differential fashion. Importantly, the length and flexibility of the
hinge region varies considerably among the IgG subclasses, and
IgG3 differs from the other subclasses by its unique extended hinge
region which is approx. four times as long as the IgG1 hinge,
leading to the most hinge-mediated flexibility among human IgG
subclasses [58]. Notably, we demonstrate efficient FccRIII
blockade by IgG3-shaped immune complexes through gp68 and
gp34 (Figure 4) which is not possible by HSV gE [36,37]. Thus,
by analogy with HSV gE, HCMV gp34 and gp68 represent
promising and unique tools to further probe into the diverse
structural requirements of FccRI/II/III activation by immune
complexes constituted by all IgG subclasses.
Functional redundancies of gp34 and gp68?
The presence of independent but redundant immunoevasins
jointly targeting one particular immune control mechanism is a
typical feature of cytomegaloviruses highlighting the antiviral
power of the targeted immune component [6,59–62]. At first
glance, the HCMV FccR antagonists gp34 and gp68 exhibit a
surprisingly similar effect on the whole range of activating host
FccRs, despite their simultaneous synthesis during the early and
late phase of HCMV replication [22]. As a consequence, removal
of both inhibitors from the surface of HCMV infected cells did not
reveal additive or even synergistic effects compatible with the
notion that the two factors do not act in an obvious cooperative
manner. This finding cannot be attributed to differences in the
density of plasma membrane resident HCMV antigens between
the HCMV gene deletion mutants compared in our study (see
Figure S2 and S3). However, both of the antagonists could
themselves represent antigens that are recognized by the F(ab) part
of immune IgG, which could either directly activate host FccRs or
block Fcc-mediated bridging of opsonizing IgG (as a counter
defense of humoral immunity against vFccRs) and thus indirectly
enhance host FccR triggering. Moreover, both of the HCMV
FccRs may fulfill further proviral but Fcc-independent functions
which exert separate pressures to adapt. This is exemplified by the
MCMV m138/fcr-1 molecule which down-regulates the NKG2D
ligands MULT-1, H60, RAE-e [46,63] as well as the B7-1
molecule CD80 [64] beyond its Fcc binding activity. In addition,
besides gp34 and gp68 additional HCMV FccRs become
expressed on infected cells (Merce´-Maldonado and Hengel, in
preparation), one of which is encoded by RL13 [65]. Thus gp34
and gp68 may be part of a much more complex network of co-
expressed HCMV FccRs jointly combating their host opponents,
and removal of one player could confound their interplay and
nested hierarchies. Next, drastic quantitative and qualitative
differences in the potency of gp34 vs. gp68 became apparent
when soluble molecules were compared. Thus it is tempting to
speculate that shedding of vFccRs may be part of the molecular
blueprint of particular vFccRs.
Which HCMV antigens elicit ADCC responses?
While there is extensive knowledge on antigens and processed
epitopes which rule anti-HCMV T cell responses [66], viral
antigens that are targets of ADCC dependent cellular immunity
remain poorly defined. Our finding that late but not early antigens
dominate the FccRIII/CD16 activating IgG response (Figure 1B)
appears a particular characteristic of HCMV when compared with
HSV and could point to structural glycoproteins known to become
exposed on the cell surface as the HCMV replication cycle
progresses, e.g. gB [67], gH [68] and UL128 [69]. Guided by
human antibodies with defined specificity, our BW5147-based
FccR-f assay system could be instrumental to identify the relevant
HCMV antigens and epitopes. In many tissues and organ
compartments, including blood, HCMV is spreading intracellu-
larly (e.g. via infected endothelial cells and leukocytes) rather than
as free virions [70]. Therefore, ADCC-inducing IgG is plausible to
represent a primary effective component of humoral immunity,
which becomes only secondary attenuated by gp34 and gp68.
Both immunoevasins could thus contribute to the relatively poor
therapeutic efficacy of HCMV-immune IgG observed in a variety
of clinical settings [12–14]. Thus a better knowledge of the optimal
HCMV IgG epitopes on the one hand, and an understanding of
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the action of viral FccR antagonists on the other hand, could
provide us with a basis for the targeted induction or even rational
synthetic design of IgG molecules that allow an improved
immunotherapy of HCMV diseases.
Materials and Methods
Cell lines, viruses and infection conditions
Human MRC-5 lung fibroblasts (ATCC CCL-171), African
green monkey CV-1 (ATCC CCL-70), HEK293 (ATCC CRL-
1573) and CD20 transfected 293T cells (a kind gift from Irvin S. Y.
Chen, University of California) [35] cells were maintained in culture
with D-MEM (Gibco), 10% (vol/vol) heat-inactivated FCS,
Penicillin (100 U/ml), Streptomycin (100 mg/ml) and Glutamine
(2 mM). Mouse BW5147 thymoma cells (obtained from ATCC,
TIB-47), transfectants thereof [28] and SKOV-3 cells were
maintained in RPMI 1640 medium with 10% (vol/vol) FBS,
Penicillin, Streptomycin, Glutamine, and Sodium Pyruvate (1 mM).
The following viruses were used: the bacterial artificial chromosome
plasmid (BACmid)-derived human cytomegalovirus (HCMV) strain
HB5 [71], the HB5-derived mutants lacking UL118-120 (Dgp68)
[22] or lacking IRL/RL11/UL118 (Dgp68/Dgp34) [31], TB40/E
BAC [34], herpes simplex virus 1 strain F (HSV-1), HSV-1 DgE and
revertant thereof [72], VACV wt Western Reserve, recombinant
VACVs expressing the vFccRs [22,73], a rVACV expressing
MULT-1 [74] and a rVACV expressing a non-IgG binding
truncation mutant of MCMV m138 (m138DIg1Flag) [46]. The
HB5-derived deletion mutant TRL10-14/IRL (Dgp34) was con-
structed following a previously published procedure [75]. The BAC
plasmid pHB5-DIRL-frt (kindly provided by Eva Borst, Hannover,
Germany), lacking the nucleotides 179150–192329 of the AD169-
derived BAC pHB5 [71] was used to generate BAC plasmid
pDIRL/DTRL11 (lacking the viral FccR gp34; Dgp34). For its
construction, the primer pair AZ-TRL11-tet1 59ACAGACGAC-
GAAGAGGACGAGGACGACAACGTCTGATAAGGAAGGCG-
AGAACGTGTTTTGTCCAGTGAATTCGAGCTCGGTAC-39
and AZ-TRL11-tet2 59TGTATACGCCGTATGCCTGTACGT-
GAGATGGTGAGGTCTTCGGCAGGCGACACGCATCTTG-
ACCATGATTACGCCAAGCTCC-39 was used to amplify the
tetracycline resistant gene (TetR) from pCP16 for insertion into
pDIRL-frt. Recombinant TB40 HCMV were generated according
to a previously published procedure [75] using BAC plasmid TB40/
BAC4 [34]. For construction of the TB40 Dgp34 mutant, a PCR
fragment was generated from the contiguous primers PL-delRL11-1
(59-TCCCCGTTGATCGAACCGACGGGCACAGACGACGA-
AGAGGACGAGGACGACGACGTCTGACCAGTGAATTCG-
AGCTCGGTAC-39) and PL-delRL11-2 (59-CATGCATGT-
TATTTGCGTGTACGATGACTTGTTTCGCCGTCGATGT-
TGTGTACGCATCTTTTACTCCAAATCCCCGTCCACCCA-
CCATGATTACGCCAAGCTCC-39) using the plasmid pSLF
RTKn [22] as template DNA. For construction of the TB40
Dgp68 mutant a PCR fragment was generated from the contiguous
primers PL-delUL119-1 (59-GGTCTCCTGCGGCCTGAGTC-
CCGAGATAAGCAGCTCTTGAGCAGTAGCGTTGTAGGA-
GAGCCAGTGAATTCGAGCTCGGTAC-39) and PL-delUL1
19-2 (59-AGGTGACGCGACCTCCTGCCACATATAGCTC-
GTCCACACGCCGTCTCGTCACACGGCAACGACCATGA-
TTACGCCAAGCTCC-39) using the plasmid pSLFRTKn [22] as
template DNA. The PCR fragments containing a kanamycin
resistance gene were inserted into TB40/BAC4 by homologous
recombination in E. coli. The Knr was excised from both BACs by
flp-mediated recombination [75] generating the HCMV BACs
TB40-Dgp34 and TB40-Dgp68. The revertant viruses were
constructed from PCR-fragments containing the respective gene
and flanking homologies subcloned into the BamHI site of the
shuttle vector pST76KSR. The following primer pairs were used:
AZ-RL11rev-1: GtGGATCCGAGTGTTGAAGGGTAACGT-
GAGGGA and AZ-RL11rev-2 GCTCTAGAGCATGCA-
GATCTGTCTTGTAGCACGATGTGGTGGT for the gp34
revertant and AZ-UL118rev-1: GCTCTAGAGCATGCAGATC-
TACCACTGCTTGAAGTAGGGCACC and AZ-UL118rev-2:
GtGGATCCGGTGGTATGAGCCTGAAGTGAGCAT for the
gp68 revertant. The viral FcR genes from plasmids pST76KSR-
RL11rev and pST76-KSR-UL119rev were inserted into TB40-
Dgp34 and TB40-Dgp68, respectively, by two-step homologous
recombination [76] resulting in the BACs TB40-gp34Rev and
TB40-gp68Rev. Correct mutagenesis of all recombinant HCMV-
BACs was confirmed by restriction analysis and sequencing of the
respective genome region. Recombinant viruses TB40-Dgp34,
TB40-Dgp68, TB40-gp34Rev and TB40-gp68Rev were reconsti-
tuted by transfection of MRC-5 using Superfect reagent (Qiagen,
Germany) as described by Borst et al. [71]. The AD169varL deletion
mutants were generated according to a previously published
procedure [75] using the BACmid-cloned AD169varL genome
pAD169 [33] as parental BACmid. Briefly, a PCR fragment was
generated using primers listed in Table S2. The PCR fragment
containing a kanamycin resistance gene was inserted into the
parental BACmid by homologous recombination in E. coli. For the
construction of mutants harboring deletions of two non-adjacent
genes, the kanamycin cassette was removed by flp-mediated
recombination before introducing the second deletion. Recombi-
nant mutant viruses were reconstituted from BACmid DNA by
Superfect (Qiagen, Germany) transfection into HCMV-permissive
MRC-5 fibroblasts.
Infection of cells with HCMV and HSV was enhanced by
centrifugation at 800 g for 30 min. If not stated otherwise, the cells
were infected with 2–3 PFU/cell.
Human immunoglobulin preparations, human serum
pools and humanized antibodies
A clinically used IVIG preparation [11] Cytotect [32,77] (batch
no. A158024 and B797053, Biotest Pharma GmbH, Germany)
containing ELISA reactive IgG specific for HCMV and HSV was
used. For the FACS analysis of HCMV and HSV surface antigens,
F(ab)2 fragments were generated from Cytotect with the Pierce
F(ab)2 Micro Preparation Kit (Thermo Fisher Scientific Inc.,
Rockland, IL, USA) according to the manufacturer’s instructions
and controlled by Western Blot (data not shown). For the
experiments with HCMV and HSV, a pool of two ELISA
seronegative donors were used as a negative control. Trastuzumab
was purchased from Genentech, Inc., USA and palivizumab from
MedImmune, USA. The humanized anti-CD20 IgG1, IgG2,
IgG3, IgG4 isotypes and IgA were purchased from InvivoGen,
Toulouse, France. For the CD107a NK degranulation assay, an
HCMV- and HSV-seropositive donor and a negative serum donor
as sources of immune and non-immune IgG, respectively, were
used. For proofing that the assay was antibody-antigen specific
(Figure S1), a pool of 6 HCMV- and HSV-seropositive donors and
a pool of 2 negative serum donors as sources of immune and non-
immune IgG, respectively, were used. For serum preparation,
blood was drawn from healthy volunteers after written informed
consent.
Ethics statement
The experiments were approved by the Ethics Committee of the
University Hospital Du¨sseldorf (no. 3410) in accordance with the
Declaration of Helsinki. For serum and NK cells preparation,
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blood was drawn from healthy volunteers after written informed
consent.
IgG dependent activation of the BW:FccR-f transfectants
This assay was described elsewhere [28]. Briefly, in a standard
assay, target cells were incubated with dilutions of human sera,
IVIG, the anti-hCD20 IgG isotype collection or trastuzumab in D-
MEM with 10% (vol/vol) FCS for 30 min at 37uC. Cells were
washed before co-cultivation with BW:FccR-f transfectants (ratio
E:T 20:1) for 16 h at 37uC in a 5% CO2 atmosphere. Then mIL-2
secreted was measured by ELISA. When applied to VACV
infected cells, a previous step of UV-inactivation at 4000 Jules/m2
and 2 steps of washing with PBS were performed before
opsonization with Abs. When applied to the inhibition through
soluble vFccR, soluble proteins were added concomitantly with
BW:FccR-f transfectants. For herpesviral late antigens IgG-
dependent activation of BW:FccRIIIA cells, late phase gene
expression was blocked by the use of phosphonoacetic acid (PAA)
(250 mg/ml), which blocks viral genome replication and late gene
expression. Afterwards, a co-cultivation assay was performed as
described above.
Expression and purification of soluble V5-His tagged
HCMV vFccR ectodomain proteins
The N-terminus of gp34 was amplified by PCR using the
following primers 59-GCTTAGGGATCCATGCAGACCTA-
CAGCACCCC-39) [22] and 59-TCTCACTAGTGGACCAC-
TGGCGTTTTAAATC-39. Cloning of the N-terminus of gp68
was previously described [24]. The N-terminus of ICOSL (ICOS
ligand) was amplified by PCR using the following primers 59-
GAGGTAAGATCTCGCACCATGCGGCTGGGC-39 and 59-
CTCTCACTAGTCGTGGCCGCGTTTTTC-39. Sequencing of
the coding sequences showed an amino acid exchange in ICOSL
from V128 to I128 but with no detectable functional difference.
Each PCR product was cloned in pGene/V5-His B vector
(Invitrogen, USA) in frame with the V5-His epitope tag using the
restriction sites BglII and SpeI (italics in primer sequences) and then
subcloned in pIRES-EGFP vector (Clontech, USA). For enhanced
expression of gp34V5-His and gp68V5-His, c-Globin cloned from
pSG5 vector (Stratagene, USA) was inserted into pIRES-EGFP
between the CMV-IE promoter and the coding sequences. The
plasmids were transfected in HEK293 cells using Superfect
(Qiagen, Germany) and transfected cells were selected with
1.25 mg/ml of Geneticin (Sigma-Aldrich, Germany). After 4–5
days, supernatants were collected, volume reduced, diluted with
PBS (1:3), adjusted to a 10 mM Imidazole concentration and
passed over a His-Trap FF crude column (GE Healthcare, USA).
Proteins were eluted in Imidazole/Phosphate buffer (250 mM
Imidazole, 20 mM sodium phosphate, 500 mM NaCl) and then
dialyzed to PBS. Comparable protein amounts were adjusted
based in Western blot analysis using a-V5 antibody (Invitrogen,
USA).
FACS analysis for vFccR expression on infected cells
MRC-5 cells were infected with 2 PFU/cell of wt HCMV
and HCMV vFccR mutants during 72 h and with HSV-1 wt,
DgE and DgE-revertant during 24 h. Cells were resuspended in
PBS containing 2 mM EDTA, washed twice in PBS supplement-
ed with 3% (vol/vol) FCS and mock stained or stained with
human Fcc fragment-FITC (Rockland Immunochemicals, USA).
16104 living cells were obtained in FACSCanto II using the
FACS Diva software and analyzed with FLowJo (Tree Star Inc,
USA).
FACS analysis for HCMV and HSV surface antigen
expression on infected cells
MRC-5 cells were infected with 1 PFU/cell of wt HCMV and
HCMV DvFccR mutants for 72 h and with 10 PFU/cell of HSV-
1 wt and DgE for 24 h. Cells were resuspended in PBS containing
2 mM EDTA, washed twice in PBS supplemented with 3% (vol/
vol) FCS. HCMV infected cells were stained with the F(ab)2
preparation of Cytotect, goat anti-human-F(ab)2-Biotin, and
Streptavidin-PE (AdB Serotec, UK) or Fcc fragment-FITC
(Rockland Immunochemicals, USA). The comparability of infec-
tion of the different HCMV DvFccR mutants was controlled by
intracellular staining of CMV nuclear antigens with CCH2 and
DDG9 antibodies (Dako, Denmark) and goat anti-mouse-APC
(BD Pharmingen, USA) after fixation with 1,5% PFA and
permeabilization with PBS supplemented with 3% (vol/vol) FCS
and 0,05% (vol/vol) Saponin. HSV infected cells were stained with
the F(ab)2 preparation of Cytotect, goat anti-human-F(ab)2-Biotin
(AdB Serotec, UK) or Fcc fragment-Biotin (Rockland Immuno-
chemicals, USA) and Streptavidin-APC (Jackson Immunore-
search, USA). After DAPI staining, 1–26104 living cells were
obtained in a FACSCanto II using the FACS Diva software and
analyzed with FlowJo (Tree Star Inc, USA).
CD107a NK cell degranulation assay
PBMCs were prepared from EDTA-blood of healthy donors
using Lymphoprep (Axis-Shield, Norway) differential centrifuga-
tion. PBMCs were incubated during 3 h at 37uC to allow
adherence of unwanted cells. Suspension cells were collected and
resuspended in media containing 100 IU/ml of human rIL-2
(PromoKine, Germany) and incubated overnight at 37uC. Cells
were resuspended and further processed to obtained polyclonal
NK cells using a MACS negative selection NK cell isolation kit
(Miltenyi Biotec, Germany). NK cell purity was tested in FACS
and was usually above 96% (data not shown). For measuring
degranulation by co-cultivation of immune IgG and a viral target,
HCMV or HSV infected fibroblasts were opsonized with a serum
of a healthy donor positive for HCMV and HSV or with IVIG. As
a control, a healthy seronegative donor was also analyzed.
Opsonization was done at 37uC for 30 min at 5% CO2. Two
steps of washing with D-MEM 10% (vol/vol) FCS followed to
remove unbound IgG. 16105 polyclonal NK cells (E:T ratio of
10:1) were added in each well and the CD107a assay was
performed as elsewhere described [43]. Briefly, polyclonal human
NK cells were incubated 4 h at 37uC in the presence of 6 mg/ml
Golgi Stop (Monensin, BD Pharmingen, Belgium), 10 mg/ml
Golgi Plug (BrefeldinA, BD Pharmingen, Belgium), and CD107-
PeCy5 mAb (BD Pharmigen, Belgium). NK cells were collected,
washed twice in ice cold PBS containing 2 mM EDTA and stained
for extracellular markers (CD56, CD3). 16104 cells were counted
and analyzed.
Immunoprecipitation and detection of proteins by
immunoblot
SKOV-3 cells were infected with 2 PFU/cell VACV for 14 h.
Infected cells were incubated with 1 mg/ml trastuzumab or
palivizumab for 30 min at 4uC, and non-bound antibody was
removed by washing cells with PBS. Lysis buffer (200 mM NaCl,
10 mM MgCl2, 10 mM KCl, 20 mM HEPES, 0.5% (vol/vol) NP-
40, 0.1M EDTA, 10% (vol/vol) glycerol, 0.1 mM sodium
orthovanadate, 0.1 mM PMSF, 0.5 mM Pepstatin, 1 mM dithio-
threitol, pH 7.4) was given to cells and, after removal of cell nuclei
by centrifugation, lysates were incubated with agarose immobi-
lized anti-FLAG antibody (Bethyl Laboratories, Inc. USA) during
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2 h at 4uC. Previously, a sample of each lysate was taken for
subsequent western blot expression analysis. Lysis buffer was used
to wash the agarose pellet and proteins were eluted with Laemmli
sample buffer. Proteins were separated by sodium-dodecyl-sulfate
(SDS)-8% polyacrylamide gel electrophoresis (PAGE) and trans-
ferred to nitrocellulose filters. Western Blot was performed with
anti-ErbB2-specific rabbit mAb V2W (Abcam Inc, USA), anti-
Flag-specific mouse mAb M2 (Sigma-Aldrich, USA), anti-human-
peroxidase (Sigma-Aldrich, USA), anti-rabbit-peroxidase (Sigma-
Aldrich, USA) and anti-mouse-peroxidase (Dianova, Germany).
Proteins were visualized using ECL chemiluminescence system
(GE-Healthcare, Germany).
Uniprot list of genes and proteins used
HCMV UL119-118: P16739
HCMV RL11: Q6SX56
HSV gE: Q703F0
Human FccRIIIA/CD16: P08637
Human FccRIIA/CD32A: P12318
Human FccRI/CD64: P12314
Mouse TCR zeta chain: P24161
Human ICOSL: O75144
Taxonomy ID for viruses
Human cytomegalovirus (strain AD169): 10360
Herpes simplex virus (type 1/strain F): 10304
Vaccinia virus Western Reserve: 696871
Supporting Information
Figure S1 BW:FccR-f responses are virus-specific and
triggered only in the presence of virus-immune IgG.
MRC-5 cells were infected with 2 PFU/cell HSV-1 wt, HCMV
HB5 wt or left uninfected (mock) for 24 or 72 h. Afterwards, cells
were opsonized with IgG of pooled human sera. ELISA-reactive
(immune) HSV IgG and HCMV IgG sera were compared with
ELISA non-reactive (non-immune) sera at 2 mg/ml of IgG
concentration. After washing, BW:FccR-f effector cells were
added and cultures were incubated for 16 h. mIL-2 was
determined by ELISA. Triplicates were measured; means with
standard deviations (error bars) are shown for 2 independent
experiments. n.d. indicates OD,0.05.
(TIF)
Figure S2 Detection of HCMV and HSV surface antigen
expression on infected cells. (A) MRC-5 cells were infected
with HSV-1 wt, DgE and DgE-revertant with 2 PFU/cell for 24 h.
After harvesting and washing in PBS with 3% (vol/vol) FCS cells
were mock stained, stained with human Fcc-FITC or stained with
a purified F(ab)2 preparation of Cytotect, followed by goat anti-
human-F(ab)2-Biotin and Streptavidin-PE. 1610
4 living cells were
analyzed with a FACSCanto II using the FACS Diva software and
analyzed with FLowJo (Tree Star Inc, USA). (B) As in (A), but
MRC- 5 fibroblasts were infected with HCMV HB5 wt or
HB5Dgp68 with 2 PFU/cell for 72 h. (C) as in (B), but MRC-5
cells were infected with HB5DIRL, HB5DIRLDgp34 or
HB5DIRLDgp34/Dgp68. (D) As in (B), but MRC-5 cells were
infected with AD169varL wt, AD169varLDgp68, AD169-
varLDgp34 or AD169varLDgp34/Dgp68. One of three (A, B, C)
or two (D) representative experiments is shown.
(TIF)
Figure S3 HCMV TB40/E BACmid derived vFccR
revertants restore FccRIIIA inhibition. MRC-5 cells were
infected with HCMV wt virus, vFccR mutants or vFccR
revertants (2 PFU/cell) for 96 h. (A) Infected MRC-5 fibroblasts
were stained with purified F(ab)2 fragments prepared from IVIG
Cytotect, Fcc-FITC or 2nd step antibody as a control and analysed
by FACS. (B) MRC-5 fibroblasts were opsonized with IVIG
Cytotect at different concentrations for 30 min. After removing of
unbound antibodies by washing, 16105 BW:FccR-f transfectants
were added. Measurement of mIL-2 in supernatants after 16 h of
co-cultivation of reporter cells with targets was performed by
ELISA. Values are presented in the graphic as OD 450 nm. n = 3;
means with standard deviations (error bars) are shown for two
independent experiments.
(TIF)
Figure S4 Ectopic expression of HSV-1 gE, HCMV gp68
and HCMV gp34 inhibit IgG1 mediated activation of
FccRIIA. CD20 transfected 293T cells were infected for 16 hours
with 2 PFU/cell of VACV wt or rVACV expressing gE (A) or
gp68 and gp34 (B). After opsonization with 4 mg of rituximab
(anti-hCD20 IgG1) and washing for removing unbound antibody,
cells were co-cultivated with 16105 BW:FccRIIA-f reporter cells
per well for 16 h before supernatants were collected and mIL-2
was determined by ELISA. Each value represents three replicates;
means with standard deviations (error bars) are shown for two
independent experiments. Significance of results (Student’s t-test)
are presented in Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001.
(TIF)
Figure S5 Detection of soluble vFccRs ectodomains. To
compare amounts of soluble proteins used in the BW:FccR-f
assay, recombinant proteins were loaded in different dilution steps
on an SDS-PAGE and detected using an anti-V5 antibody by
western blot. Due to the strong inhibition capacity of sgp34
protein at very low concentrations, its amounts are hardly
detectable in the blot. Therefore higher concentrations (2006,
1006) and a longer exposure are shown.
(TIF)
Table S1 Significance of results (Student’s t-test) is presented in
Table S1 as *: p,0.05 **: p,0.01 ***: p,0.001 for all figures in
need of it.
(DOCX)
Table S2 Synopsis of HCMV mutants used in the study.
(DOCX)
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